Τρίτη 4 Απριλίου 2017

AACR 2017: IDH-mutant cancers may be more amenable to PARP inhibition than IDH inhibition

Tumours with mutations in the proteins isocitrate dehydrogenase-1 or -2 (IDH1/2) exhibited features similar to BRCA-mutant tumours and were more likely to respond better to PARP inhibitors than to IDH inhibitors, according to preclinical data presented at...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nzKoTC
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις